Assuming you don't believe Dendreon is lying to their shareholders like SPPI did on satraplatin's SPA, there is no basis for a charge the trial is "poorly constructed." The Seeking Alpha blogger said the IMPACT trial was not poorly constructed. Did you miss the word not?